Test Price
2,800 AED✅ Home Collection Available
AMHR2 Gene (Persistent Mullerian Duct Syndrome Type 2) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by DHA-licensed genetics specialists for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) test detects pathogenic variants in the AMHR2 gene associated with Persistent Mullerian Duct Syndrome type 2 (PMDS), a rare 46,XY difference of sex development. The assay covers the full coding region and splice sites, enabling detection of single nucleotide variants, small insertions and deletions, and copy number variations with high diagnostic sensitivity. Identification of a biallelic pathogenic mutation in AMHR2 confirms the diagnosis and guides surgical and fertility management decisions.
| Feature | Our Test (NGS) | Alternative (Single-Gene Sanger) |
|---|---|---|
| Methodology | Next-Generation Sequencing (Full coding region + splice sites) | Sanger sequencing (targeted exons only) |
| Sensitivity | >99.9% for SNVs, indels, CNVs | ~95% for common point mutations |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Clinical Reporting | DHA-aligned ICD-10 & LOINC encoded | Generic report, no standardised coding |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA: 9294403): “A molecular diagnosis of PMDS type 2 through AMHR2 sequencing provides families with a clear explanation for atypical genital development and allows for tailored surgical planning. I always remind my patients that genetic findings must be interpreted alongside imaging and clinical examination. Our counselling team ensures that every result is communicated with sensitivity and actionable guidance.”
Advisory Note on Medical Decision-Making
⚠️ Never delay prescribed therapies or surgical interventions without consulting your treating physician. Genetic test results are one component of a comprehensive clinical assessment.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active bleeding disorder, known allergy to chlorhexidine or antiseptic agents, or inability to provide a viable blood sample.
- Minors: Genetic testing of children requires informed consent from a legal guardian and mandatory pre-test genetic counselling per UAE regulatory standards.
- Emergency Red Flags (post-collection): Seek immediate medical attention if you experience excessive bruising, persistent oozing, fever, or severe pain at the venipuncture site.
Patient FAQ & Clinical Guidance
1. What does the AMHR2 test detect, and why is it ordered?
This NGS-based analysis identifies disease-causing variants in the AMHR2 gene that lead to Persistent Mullerian Duct Syndrome type 2, a condition in which 46,XY individuals retain Mullerian structures (uterus, fallopian tubes, upper vagina). The test is typically requested when a male infant presents with cryptorchidism, inguinal hernia containing Mullerian remnants, or during infertility evaluation in adults with suspected PMDS.
2. How is the sample collected, and do I need to prepare?
We provide VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM. A small peripheral blood sample (2–5 mL) is drawn into an EDTA tube; no fasting is required. A certified genetic counsellor will obtain a detailed family pedigree prior to collection to ensure complete clinical context.
3. What is the turnaround time and what do the results mean?
Final results are delivered within 3 to 4 weeks. A positive result confirms a molecular diagnosis of AMHR2-related PMDS, guiding surgical decisions and reproductive counselling. A negative result does not exclude other genetic causes of 46,XY DSD and may warrant broader genomic investigation or endocrine assessment.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient genetic data handling. Additionally, all health information systems adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure storage, encrypted transmission, and limited access to authorised clinical personnel only. Clinical testing safety and patient consent follow the standards set by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | AMHR2 Gene (Persistent Mullerian Duct Syndrome Type 2) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available |
| Methodology Used | Next-Generation Sequencing (NGS) – full coding region and splice sites |
| ICD-10-CM Code | Q55.8 |
| LOINC Code | 21659-2 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians